B
Bull
Bull · 25%AVDL
$40.13
Precio del escenario
$21.640
+0.011 (+0.05%)Al cierre
Loading chart…
- High
- 21.760
- Open
- 21.660
- VWAP
- 21.68
- Vol
- 35.02M
- Mkt Cap
- 1.38B
- Low
- 21.630
- Amount
- 759.04M
- EV/EBITDA, TTM
- 27.98
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
AI analysis of Avadel Pharmaceuticals PLC (AVDL)
holdAvadel Pharmaceuticals PLC (AVDL) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company's revenue growth is impressive, the recent acquisition by Alkermes introduces uncertainties, and the lack of significant trading signals or strong positive catalysts suggests holding off on immediate investment.
Analyst Ratings (5)
+0.14% upside
Buy
5 Buy
0 Hold
0 Sell
Current: 21.64
Mínimo
20.00
Promedio
21.67
Máximo
22.50
Wells Fargo
Equal Weight
$20
2025-11-20
Wells Fargo
2025-11-20
Precio objetivo
$20
Equal Weight
UBS
Neutral
$20
2025-10-28
UBS
2025-10-28
Precio objetivo
$20
Neutral
Morgan Stanley
Overweight
$183
2025-10-24
Morgan Stanley
2025-10-24
Precio objetivo
$183
Overweight
Deutsche Bank
Hold
$20
2025-10-23
Deutsche Bank
2025-10-23
Precio objetivo
$20
Hold
Piper Sandler
Overweight
$45
2025-10-23
Piper Sandler
2025-10-23
Precio objetivo
$45
Overweight
Métricas de valoración
The current forward P/E ratio for Avadel Pharmaceuticals PLC (AVDL) is 31.13, compared to its 5-year average forward P/E of 127.27.
Alphio AI Price Scenarios for AVDL
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding AVDL
Cronología de eventos
Noticias
8.502-12NewsfilterAlkermes Acquires Avadel to Expand Product Portfolio
5.001-19GlobenewswireState Street Increases Stake in Avadel Pharmaceuticals by 2.39%
- 8.501-16Globenewswire
State Street Increases Stake in Avadel Pharmaceuticals by 2.36%
- 5.001-15Globenewswire
State Street Increases Stake in Avadel Pharmaceuticals, Holding Reaches 2.36%
8.501-12Yahoo FinanceAvadel Pharmaceuticals Shareholders Approve Alkermes Buyout
AVDL FAQ — answered by Alphio AI
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Avadel Pharmaceuticals PLC (AVDL) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company's revenue growth is impressive, the recent acquisition by Alkermes introduces uncertainties, and the lack of significant trading signals or strong positive catalysts suggests holding off on immediate investment.
5 analysts cover AVDL: 5 rate it Buy, 0 Hold and 0 Sell. The average price target is 21.67.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.